Blood Test to Predict AML/MDS Relapse After Stem Cell Transplant
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a new blood test to help predict whether acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) will come back after a stem cell transplant. Early detection could help doctors treat relapse sooner.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have AML or MDS (including CMML) and are getting a stem cell transplant
- Your transplant is from a matched or partially matched donor (not an identical twin)
- You are in complete remission (cancer not detectable) 30 days after transplant
- Your transplant used standard conditioning (chemotherapy), not T-cell depletion
- You have not had a previous stem cell or organ transplant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a type of stem cell transplant (using cells from a partially matched donor and umbilical cord blood) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The goal is to help patients whose disease is high-risk, has returned after treatment, or hasn't responded well to chemotherapy.
This study uses a special blood test to see if it can predict which patients with a specific type of acute myeloid leukemia (AML with MLL changes) are more likely to relapse or have better survival. The test may help doctors plan better treatment.
This trial checks if using advanced tests to find leftover cancer cells before a stem cell transplant can help prevent the disease from coming back. If you have a myeloid blood cancer, you might be able to join.
This study looks at a personalized lab test to detect small amounts of disease after a stem cell transplant and then decide what treatment comes next. It may help some people with certain bone-marrow diseases stay in remission while avoiding unnecessary treatment.
This trial tests an injection of donor-derived immune cells (called RC1012) to lower the chance of AML coming back after an allogeneic stem cell transplant. It is aimed at people at higher risk of relapse once the transplant is completed.
This trial checks how certain blood “biomarkers” change after you receive donor stem cells to rebuild your blood and immune system. The goal is to learn whether these markers can better predict your immune recovery after transplant.
Hear when a new AML (Acute Myelogenous Leukemia) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.